{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T22:58:54Z","timestamp":1768345134082,"version":"3.49.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T00:00:00Z","timestamp":1700524800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical Co., Ltd.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Minimal residual disease assessment of BCR-ABL messenger ribonucleic acid levels is crucial in Philadelphia chromosome-positive acute lymphoblastic leukemia for prognosis and treatment planning. However, accurately quantifying minor BCR-ABL transcripts, which comprise 70% of Philadelphia chromosome-positive acute lymphoblastic leukemia cases, lacks a national-approved method.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We developed the \u201cOtsuka\u201d minor BCR-ABLmessenger ribonucleic acid assay kit with exceptional precision (0.00151%). Minor BCR-ABL messenger ribonucleic acid levels were analyzed in 175 adults, 36 children with acute lymphoblastic leukemia and 25 healthy individuals to evaluate the kit\u2019s performance.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The \u201cOtsuka\u201d kit showed high concordance with a commonly used chimeric gene screening method, indicating reliable detection of positive cases. Quantitative results demonstrated a robust correlation with both a laboratory-developed test and a diagnostic research product. The \u201cOtsuka\u201d kit performs comparably or even surpass to conventional products, providing valuable insights into Philadelphia chromosome-positive acute lymphoblastic leukemia pathology.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The \u2018Otsuka\u201d minor BCR-ABL messenger ribonucleic acid assay kit exhibits excellent performance in quantifying minor BCR-ABL transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia patients. Our results align well with established screening methods and show a strong correlation with laboratory-developed tests and diagnostic research products. The \u201cOtsuka\u201d kit holds great promise as a valuable tool for understanding Philadelphia chromosome-positive acute lymphoblastic leukemia pathology and guiding effective treatment strategies.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyad156","type":"journal-article","created":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T07:16:30Z","timestamp":1700550990000},"page":"153-159","source":"Crossref","is-referenced-by-count":2,"title":["Development and evaluation of a rapid one-step high sensitivity real-time quantitative PCR system for minor <i>BCR-ABL<\/i> (e1a2) test in Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)"],"prefix":"10.1093","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8645-2184","authenticated-orcid":false,"given":"Michihiro","family":"Hidaka","sequence":"first","affiliation":[{"name":"Department of Hematology , National Hospital Organization Kumamoto Medical Center, Kumamoto , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koiti","family":"Inokuchi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nippon Medical School , Tokyo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiko","family":"Uoshima","sequence":"additional","affiliation":[{"name":"Department of Hematology, Japanese Red Cross Kyoto Daini Hospital , Kyoto , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Hematology , Nephrology and Rheumatology, , Akita , Japan"},{"name":"Akita University Graduate School of Medicine , Nephrology and Rheumatology, , Akita , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nao","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology , Children's Medical Center, , Aichi , Japan"},{"name":"Japanese Red Cross Aichi Medical Center Nagoya First Hospital , Children's Medical Center, , Aichi , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuichi","family":"Ota","sequence":"additional","affiliation":[{"name":"Department of Hematology, Sapporo Hokuyu Hospital , Hokkaido , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirohisa","family":"Nakamae","sequence":"additional","affiliation":[{"name":"Department of Hematology , Graduate School of Medicine, , Osaka , Japan"},{"name":"Osaka City University , Graduate School of Medicine, , Osaka , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromi","family":"Iwasaki","sequence":"additional","affiliation":[{"name":"Department of Hematology , National Hospital Organization Kyushu Medical Center, Fukuoka , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichiro","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Shizuoka Children\u2019s Hospital , Shizuoka , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Kosaka","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology , Center of Childhood Cancer, , Hyogo , Japan"},{"name":"Hyogo Prefectural Kobe Children\u2019s Hospital , Center of Childhood Cancer, , Hyogo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Komatsu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Juntendo University School of Medicine , Tokyo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuniaki","family":"Meguro","sequence":"additional","affiliation":[{"name":"Department of Hematology , National Hospital Organization Sendai Medical Center, Miyagi , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuho","family":"Najima","sequence":"additional","affiliation":[{"name":"Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital , Tokyo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Eto","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hamanomachi Hospital , Fukuoka , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Kondo","sequence":"additional","affiliation":[{"name":"Blood Disorders Center, Aiiku Hospital , Hokkaido , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Hematology , Respiratory Medicine and Oncology, , Saga , Japan"},{"name":"Saga University , Respiratory Medicine and Oncology, , Saga , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chikashi","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Hospital Organization Mito Medical Center , Ibaraki , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya University Graduate School of Medicine , Aichi , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Sawa","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Anjo Kosei Hospital , Aichi , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Hata","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nagasaki University Hospital , Nagasaki , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keizo","family":"Horibe","sequence":"additional","affiliation":[{"name":"Department of Pediatrics , National Hospital Organization Nagoya Medical Center, Aichi , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroatsu","family":"Iida","sequence":"additional","affiliation":[{"name":"Department of Hematology , National Hospital Organization Nagoya Medical Center, Aichi , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Shimomura","sequence":"additional","affiliation":[{"name":"Department of Hematology , National Hospital Organization Hiroshimanishi Medical Center, Hiroshima , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuaki","family":"Dobashi","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology and Hematology, The Jikei University Daisan Hospital , Tokyo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isamu","family":"Sugiura","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Toyohashi Municipal Hospital , Aichi , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0883-2920","authenticated-orcid":false,"given":"Junya","family":"Makiyama","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Institute of Medical Science, The University of Tokyo Hospital , Tokyo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoyuki","family":"Miyagawa","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology , Kanagawa Children\u2019s Medical Center, Kanagawa , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asuka","family":"Sato","sequence":"additional","affiliation":[{"name":"Diagnostic Division, Otsuka Pharmaceutical Co. Ltd. , Tokushima , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuta","family":"Ito","sequence":"additional","affiliation":[{"name":"Diagnostic Division, Otsuka Pharmaceutical Co. Ltd. , Tokushima , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itaru","family":"Matsumura","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology, Kindai University Faculty of Medicine , Osaka , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuzuru","family":"Kanakura","sequence":"additional","affiliation":[{"name":"Sumitomo Hospital , Osaka , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoki","family":"Naoe","sequence":"additional","affiliation":[{"name":"National Hospital Organization Nagoya Medical Center , Aichi , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,11,20]]},"reference":[{"key":"2024020717401627000_ref1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1365-2354.2005.00513.x","article-title":"A systematic literature review of the clinical and epidemiological burden of acute lymphoblastic leukaemia (ALL)","volume":"14","author":"Redaelli","year":"2005","journal-title":"Eur J Cancer Care"},{"key":"2024020717401627000_ref2","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s11912-012-0247-7","article-title":"Philadelphia-positive acute lymphoblastic leukemia: current treatment options","volume":"14","author":"Liu-Dumlao","year":"2012","journal-title":"Curr Oncol Rep"},{"key":"2024020717401627000_ref3","doi-asserted-by":"crossref","first-page":"6411","DOI":"10.3390\/ijms22126411","article-title":"Genomic analyses of pediatric acute lymphoblastic leukemia Ph+ and Ph-like-recent progress in treatment","volume":"22","author":"Kaczmarska","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2024020717401627000_ref4","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1182\/blood.V78.9.2411.2411","article-title":"Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia","volume":"78","author":"Kantarjian","year":"1991","journal-title":"Blood"},{"key":"2024020717401627000_ref5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2014.00054","article-title":"Current concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"4","author":"Bernt","year":"2014","journal-title":"Front Oncol"},{"key":"2024020717401627000_ref6","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.2005.03.2177","article-title":"High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group","volume":"24","author":"Yanada","year":"2006","journal-title":"J Clin Oncol"},{"key":"2024020717401627000_ref7","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s00277-018-3323-8","article-title":"Final analysis of the JALSG Ph+ALL202 study: tyrosine kinase inhibitor-combined chemotherapy for Ph+ALL","volume":"97","author":"Hatta","year":"2018","journal-title":"Ann Hematol"},{"key":"2024020717401627000_ref8","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/bloodadvances.2021004607","article-title":"Dasatinib-based 2-step induction for adults with Philadelphia chromosome\u2013positive acute lymphoblastic leukemia","volume":"6","author":"Sugiura","year":"2022","journal-title":"Blood Adv"},{"key":"2024020717401627000_ref9","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1182\/blood-2016-02-700153","article-title":"Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL","volume":"128","author":"Rousselot","year":"2016","journal-title":"Blood"},{"key":"2024020717401627000_ref10","doi-asserted-by":"crossref","first-page":"e170580","DOI":"10.1001\/jamaoncol.2017.0580","article-title":"Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis","volume":"3","author":"Berry","year":"2017","journal-title":"JAMA Oncol"},{"key":"2024020717401627000_ref11","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood-2012-11-466482","article-title":"Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy","volume":"122","author":"Ravandi","year":"2013","journal-title":"Blood"},{"key":"2024020717401627000_ref12","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/bmt.2015.217","article-title":"Impact of MRD and TKI on allogeneic hematopoietic cell transplantation for Ph+ALL: a study from the adult ALL WG of the JSHCT","volume":"51","author":"Nishiwaki","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"2024020717401627000_ref13","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1007\/s12185-021-03094-x","article-title":"Minimal residual disease (MRD) positivity at allogeneic hematopoietic cell transplantation, not the quantity of MRD, is a risk factor for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"113","author":"Akahoshi","year":"2021","journal-title":"Int J Hematol"},{"key":"2024020717401627000_ref14","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1080\/1042819021000040206","article-title":"Rapid screening of leukemia fusion transcripts in acute leukemia by real-time PCR","volume":"43","author":"Osumi","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"2024020717401627000_ref15","volume-title":"ipsogen BCR-ABL1 mbcr Controls Kit [Internet]"},{"key":"2024020717401627000_ref16","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood-2002-02-0360","article-title":"Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome\/Bcr-Abl\u2013positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571)","volume":"101","author":"Scheuring","year":"2003","journal-title":"Blood"},{"key":"2024020717401627000_ref17","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1182\/blood.V73.8.2165.2165","article-title":"Detection of two alternative BCR\/ABL mRNA junctions and minimal residual disease in Philadelphia chromosome positive chronic myelogenous leukemia by polymerase chain reaction","volume":"73","author":"Lee","year":"1989","journal-title":"Blood"},{"key":"2024020717401627000_ref18","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.3324\/haematol.11737","article-title":"Atypical BCR-ABL mRNA transcripts in adult acute lymphoblastic leukemia","volume":"92","author":"Burmeister","year":"2007","journal-title":"Haematologica"},{"key":"2024020717401627000_ref19","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1182\/bloodadvances.2021004234","article-title":"Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia","volume":"5","author":"Muffly","year":"2021","journal-title":"Blood Adv"},{"key":"2024020717401627000_ref20","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1038\/s41375-019-0413-0","article-title":"Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1","volume":"33","author":"Pfeifer","year":"2019","journal-title":"Leukemia"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/54\/2\/153\/56610698\/hyad156.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/54\/2\/153\/56610698\/hyad156.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T17:56:16Z","timestamp":1707328576000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/54\/2\/153\/7434433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,20]]},"references-count":20,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,11,20]]},"published-print":{"date-parts":[[2024,2,7]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyad156","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,2]]},"published":{"date-parts":[[2023,11,20]]}}}